The FDA has approved an investigational new drug application from Ceruvia Lifesciences to conduct a phase 2 clinical trial to determine the safety and efficacy of synthetic psilocybin for the treatment of obsessive-compulsive disorder.
“With positive preliminary results from a Ceruvia-funded pilot phase 2 study taking place at Yale School of Medicine, we are excited to have received FDA